3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressings

CRBSIs

ClinicallyProven

to Reduce

2

Catheter-related bloodstream infections (CRBSIs) are one of the most serious and costly health care-acquired infections (HAIs), leading to increased costs associated with extended hospital stays, illness and death. The estimated average cost for treating a single CRBSI is $29,5001 per episode in Australia and between $20,000 to $54,0002 in New Zealand.

While recent industry and facility initiatives have led to a significant reduction in the risks, costs and incidence of CRBSIs, even one CRBSI is one too many.

Even if your rates are low, you can help your facility reduce CRBSIs by making 3M™ Tegaderm™ CHG I.V. Securement Dressings a key component of your practice.

Proven to Reduce the Risks of CRBSIsIn the largest randomised controlled trial ever conducted to evaluate the use of a CHG-containing gel dressing, including 4,163 catheters applied to 1,879 patients, 3M™ Tegaderm™ CHG Dressings were proven to signifcantly reduce CRBSIs when used in combination with other best practice interventions.3 (See Figure 1).

• Clinically proven to reduce CRBSIs by 60%3

• Proven to reduce the risk of skin and catheter colonisation, and to suppress regrowth of skin organisms commonly associated with CRBSIs3-5

• Proven to be as effective, or better than BIOPATCH® Protective disk, at reducing skin flora and preventing regrowth4,6

• Offers the same level of antimicrobial activity at day ten as day one6

• Continues to be effective in the presence of blood, saline and exudate6

Note: 3M™ Tegaderm™ CHG I.V. Securement Dressing is not indicated to replace sutures for short-term Central Venous Catheters (e.g. jugular, subclavian, femoral).

You Can Count OnProven Protection

Figure 1: Reduces CRBSIs & Catheter Colonisation

Control Tegaderm

EPIS

OD

ES/1

,000

CA

THET

ER D

AY

S

CATHETER COLONISATION

CR-BSIs MAJOR CRI CLABSI

3

0

2

4

6

8

10

12

14

3

All-in-one Antimicrobial Transparent Film Dressing-Provides Comfort and Protection• Transparent film allows continuous observation around the entire insertion site.

• Tegaderm™ Film integrated with 2% w/w Chlorhexidine Gluconate gel pad conforms to body contours and flexes with patient movement.

• Semi-permeable, highly breathable film.

• CHG is immediately and continuously available, does not require additional moisture.

• The all-in-one antimicrobial transparent dressing minimises opportunity for error.

Enables Continuous Site VisibilityThe CDC recommends the use of transparent film dressings for I.V. site care, because they: “…permit continuous visual inspection of the catheter site, permit patients to bathe and shower without saturating the dressing, and require less frequent changes than do standard gauze and tape dressings.” 7

You Can Count OnProven Protection

All-in-one transparent film dressing enables continuous site observation to monitor for signs of infection.

Delivers Exceptional Securement• Reinforced stabilisation borders and notches designed for advanced securement

• Soft cloth border adhesive forms seal around catheter site

• Sterile stablisation tape strip allow the dressing to withstand additional pull force*

Supports I.V. Site Care Best Practices and Protocols• Provides a waterproof, sterile barrier to external contaminants including liquids, bacteria and viruses**

• Allows continuous site observation to monitor for signs of infection, as recommended by the CDC Guideline7, and the Intravenous Nursing New Zealand.8

• Meets INS and CDC definitions as a catheter securement or stabilisation device

• Research has shown Tegaderm™ CHG Dressings are easy to use and fit into clinical practice as easily as other transparent dressings.9–10

• Tegaderm™ CHG Dressings can be safely worn for up to seven days—until the dressing is soiled or no longer intact—or for the length of facility protocol.

• The transparent film allows for effective oxygen-vapor exchange while helping protect against external contaminants, including those most commonly associated with CRBSIs.**

*3M internal data on file. ** In vitro testing shows that the transparent film of 3M™ Tegaderm™ CHG I.V. Securement Dressing provides a viral barrier from viruses 27 nm in diameter or larger while the dressing remains intact without leakage. Note: 3M™ Tegaderm™ CHG I.V. Securement Dressing is not indicated to replace sutures for short-term Central Venous Catheters (e.g. jugular, subclavian, femoral).

3M ™ Tegaderm™ Film Antimicrobial CHG Gel

FLUIDS

VIRUSES

BA

CTERIAWATER

OXYGEN

MOI

STUR

E VA

POR and CO 2

4

3M™

TEGADERM™

DRESSING (CONTROL)3M™ TEGADERM™ CHG DRESSING

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

N=31 31 31 31 31 30 30 30 30 29 30BASELINE POST-PREP

MEA

N LO

G C

OUN

T LO

G 10 CF

U/CM

2

BIOPATCH®

****

**

*

Figure 3: Maintains Low Skin Counts4

3M™ Tegaderm™ CHG Dressings maintained significantly lower counts than BIOPATCH ® Protective Disk or control dressings after 7 days on healthy adult subjects. ** represents p-values < 0.001, * represents p-values < 0.01.

DAY 1 DAY 4 DAY 7

MUCH BETTER OR BETTER

SAME AS MUCH WORSEOR WORSE

81%

10% 10%

0%

10%

20%

30%

40%

50%

60%

90%

70%

80%

Figure 4: Overall Performance 3M™ Tegaderm™ CHG Dressing versus BIOPATCH® Protective Disk14

3M™ Tegaderm™ CHG Dressings rated significantly better than BIOPATCH ® Protective Disk and transparent dressing in overall performance (p<0.0001).

Proven to Perform Better than BIOPATCH® Protective DiskIn studies comparing BIOPATCH® Protective Disk with CHG and a transparent adhesive cover dressing against Tegaderm™ CHG I.V. Securement Dressings on the unprepped skin of healthy adult subjects, Tegaderm™ CHG Dressings were proven to be:

• As effective, or better, at reducing skin flora for up to 10 days (see Figure 2)

• More effective at preventing regrowth at 7 days

• Significantly better at maintaining low skin counts (see Figure 3)4,6,11

• With the integrated soft gel pad, the CHG is immediately active and does not need additional moisture to activate and begin attacking skin flora

The CHG gel pad’s unique size, shape and composition provide a greater zone of antimicrobial activity than the sponge disk. The larger gel pad surface area allows for coverage of sutures as well as the insertion site.*

Preferred by CliniciansAs part of a clinical evaluation, professional I.V. nurses were trained in proper application and removal techniques for BIOPATCH® Protective Disk and Tegaderm™ CHG Dressings. They were asked to apply the dressings immediately after training. Tegaderm™ CHG Dressings were rated significantly better in:

• Overall performance (see Figure 4)

• Ease of correct application

• Ability to see the I.V. site

• Ease of training another clinician

• More intuitive to use12

In other studies:

• Nurses recommended a switch to Tegaderm™ CHG for PICC lines, IJ insertion sites and non tunnelled CVC-subclavian insertion sites13-14

• Determined the CHG gel dressing demonstrated superior performance and intuitive use15

• Determined that the ability to visually inspect the insertion site is in compliance with best practice guidelines.15

*With the integrated soft gel pad, the CHG is immediately active and does not need additional moisture to activate and begin attacking skin flora.

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

0 1 2 3 4 5 6 7 8 9 10

DAYS

BIOPATCH® 3M™ TEGADERM™ CHGDRESSING

LOG

CFU/

CM2 ±

SEM

Figure 2: In vivo time kill of flora6

In vivo time kill of normal flora on unprepped skin with the two CHG dressings on healthy adult volunteers (P=0.008).

-

-

-

5

Highly breathable transparent film

• Provides continuous site observation

• Conforms to body contours, flexes with patient movement

• Semi-permeable, breathable and improved securement

• Provides a waterproof, sterile barrier to external contaminants including liquids, bacteria and viruses*

• Latex-free

CHG Gel Pad

• Clinically proven to reduce the risk of skin and catheter colonisation

• 2% w/w Chlorhexidine Gluconate

• The absorptive CHG gel pad protects even in the presence of blood, saline and exudate

• CHG is immediately and continuously available, does not require additional moisture.

Sterile tape strips

• Enhance stabilisation, allowing the dressing to withstand additional pull force**

• Improve protocol compliance

• Are precut for anchoring hubs, lumens and tubing

• Preprinted labels for documenting dressing changes

Picture Frame Delivery

• Design makes placement accurate and easy

• Minimises potential to stick to gloves or to itself

Advanced Catheter Securement

• Reinforced stabilisation borders and notch designed for advanced securement

• Soft cloth border adhesive forms seal around catheter site

• Patterned film adhesive holds strongly,manages moisture and releases gently

• When applied with firm pressure, adhesives permeate irregular surfaces of skin, increasing the total area of contact for improved adhesion

• Adhesives build strength over the first 24 hours

• Adhesive CHG gel pad conforms around catheter hub.

* In vitro testing shows that the transparent film of 3M™ Tegaderm™ CHG I.V. Securement Dressing provides a viral barrier from viruses 27 nm in diameter or larger while the dressing remains intact without leakage. **3M internal data on file.

1658R 1659R1657R 1660RAvailable in NZ only

6

Proven Protection for All Your I.V. Site NeedsAll-in-one antimicrobial transparent film dressing provides visibility, comfort and protection.

Internal Jugular

PICC

Subclavian

Arterial

TegadermTM CHG: Proven effectiveness against the following pathogens:

Most catheter-related infections (~60%) are caused by Gram-positive microorganisms belonging to the resident skin flora (mainly coagulase-negative staphylococci and Staphylococcus aureus).16

Staphylococcus epidermidis (including MRSE) Klebsiella pneumoniae

Staphylococcus aureus (including MRSA and GRSA) Pseudomonas aeruginosa

Enterococcus faecium (including VRE) Acinetobacter baumanii

Enterococcus faecalis (including MDR) Serratia marcescens

Escherichia coli

Enterobacter cloacae

Candida albicans

Tegaderm™ CHG I.V. Securement Dressings are not indicated to replace sutures for short-term Central Venous Catheters (e.g. jugular, subclavian, femoral).

7

Ordering Information

Product Code

Overall Dressing Size

Gel Pad Size Suggested DevicesDressing/

BoxBoxes/Cases

1657R 8.5cm x 11.5cm 3cm x 4cmAll CVCs, Arterial, Dialysis, Midline,

Other percutaneous devices25 4

Product Code

Overall Dressing Size

Gel Pad Size Suggested DevicesDressing/

BoxBoxes/Cases

1658R 10cm x 12cm 3cm x 4cm All CVCs,PICC 25 4

Product Code

Overall Dressing Size

Gel Pad Size Suggested DevicesDressing/

BoxBoxes/Cases

1659R 10cm x 15.5cm 3cm x 7cm All CVCs, PICC 25 4

Product Code

Overall Dressing Size

Gel Pad Size Suggested DevicesDressing/

BoxBoxes/Cases

1660R* 7cm x 8.5cm 2cm x 2cmAll CVCs, Arterial, Midline, Other

percutaneous devices25 4

*Available in NZ only

© 2013, 3M. All rights reserved. 3M and Tegaderm are trademarks of 3M. BIOPATCH is a trademark of Johnson and Johnson.

3M New Zealand Limited94 Apollo Drive, RosedaleAuckland 0632Phone 0800 80 81 82www.3M.com/healthcare

3M Critical & Chronic Care Solutions Division

3M Australia Pty LimitedABN 90 000 100 096Building A, 1 Rivett RoadNorth Ryde NSW 21131300 363 878www.3M.com.au/healthcare

References1. Collignon PJ et al (2007) Intravascular catheter bloodstream infections: an effective and sustained hospital-wide prevention program over 8 years.

MJA Vol 187, No 10;p.551-5542. Seddon ME, et al (2011). Aiming for zero: decreasing central line associated bacteraemia in the intensive care unit. New Zealand Medical Journal

(NZMA), July 2011; Vol 124 No 1339.3. Timsit JF, et al. (2011) Randomized Controlled Trial of Chlorhexidine Dressing and Highly Adhesive Dressing for Preventing Catheter-related Infections

in Critically Ill Adults. American Journal of Respiratory and Critical Care Medicine. Vol 186, Number 12; p.1272-12784. Bashir MH, et al. (2012) Suppression of regrowth of normal skin flora under chlorhexidine gluconate dressings applied to chlorhexidine gluconate-

prepped skin. American Journal of Infection Control, 40(4):344-8.5. Karpanen TJ, et al. (2011) Antimicrobial activity of a Chlorhexidine intravascular catheter site gel dressing, Journal of Antimicrobial Chemotherapy,

66:1777-1784.6. Maki DG et al (2008). A novel integrated chlorhexidine-impregnated transparent dressing for prevention of vascular catheter-related bloodstream

infection: a prospective comparative study in healthy volunteers. Poster presented at the 18th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; April 2008, Orlando FL.

7. Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-related Infections. Healthcare Infection Control Practices Advisory Committee (HICPAC); (Appendix 1). Clin Infect Dis. 2011;52(9):e162.

8. Intravenous Nursing New Zealand. Provisional Infusion Therapy Standards of Practice. March 20129. Olson C (2008). Clinical Performance of a New Transparent Chlorhexidine Gluconate Central Venous Catheter Dressing. Journal of the Association for

Vascular Access (JAVA). March;Vol 13, No 1; p13-1910. Rupp ME (2008). Prospective, Randomized, Controlled Trial Assessing the Clinical Performance of a Transparent Chlorhexidine Gel Pad Intravascular

Catheter Dressing. Poster presented at SHEA, April 2008.11. In vivo, in vitro 3M data on file.12. Eyeberg C (2008) A Controlled Randomized Prosepective Comparative Pilot Study to Evaluate the Ease of Use of a Transparent Chlorhexidine

Gluconate Gel Dressing Versus A Chlorhexidine Gluconate Disk in Healthy Volunteers. Journal of the Association for Vascular Access (JAVA). Vol 13, No.3; p. 112-117

13. Deschneau M (2008). A Multicenter prospective open label evaluation of the clinical performance of a chlorhexidine gluconate antimicrobial transparent dressing. Poster presented at Infusion Nurses Society Conference May 2008.

14. Zeher C et al (2009) Product evaluation of a new CHG dressing for catheter care. Poster presented at Infusion Nurses Society Conference May 2009.15. Moureau N et al (2009) Evaluation of the clinical performance of a chlorhexidine gluconate antimicrobial transparent dressing. Journal of Infection

Prevention. Vol 10, Supplement 1;S13-S1716. Muñoz P et al. (2004). Clinical-epidemiological characteristics and outcome of patients with catheter-related bloodstream infections in Europe

(ESGNI-006 Study). Clin Microbiol Infect. Vol 10, No. 9;p843-845